Picard Medical will ring the NYSE Opening Bell, marking its public market transition and commitment to artificial heart therapy.
Quiver AI Summary
Picard Medical, Inc. announced its transition to the public markets by ringing the Opening Bell at the New York Stock Exchange on December 18, 2025. As the parent company of SynCardia Systems, which produces the world’s first total artificial heart approved by the FDA and Health Canada, Picard highlights its commitment to advancing therapy for patients with end-stage heart failure. CEO Patrick NJ Schnegelsberg expressed pride in this milestone, emphasizing the company’s goal to strengthen its artificial heart platform, including the fully implantable Emperor system, and to build on its clinical leadership. SynCardia’s Total Artificial Heart is the only commercially available heart of its kind in the U.S. and Canada, with over 2,100 implants performed globally.
Potential Positives
- Picard Medical is marking its transition to a public company by ringing the Opening Bell at the New York Stock Exchange, which highlights its growth and visibility in the financial markets.
- The company’s total artificial heart technology is both FDA and Health Canada approved, positioning it as a leader in medical innovation for end-stage heart failure treatment.
- With over 2,100 implants performed in 27 countries, the SynCardia Total Artificial Heart is the most widely used and researched artificial heart globally, showcasing its established market presence and clinical validation.
- The transition to a public company is expected to enhance Picard Medical’s ability to advance its artificial heart platform and create long-term value, potentially leading to further innovations and improvements in patient care.
Potential Negatives
- Forward-looking statements included in the release highlight potential risks and uncertainties that could negatively impact future performance and mislead investors.
- The company explicitly disclaims any obligation to update forward-looking statements, possibly leading to a lack of transparency for shareholders about future risks and developments.
- The emphasis on "transition to public markets" may raise questions about the company's previous private operations and whether this transition reflects a need for broader capital or indicates past difficulties in funding.
FAQ
What is Picard Medical, Inc. known for?
Picard Medical is known for being the parent company of SynCardia Systems, the maker of the world’s first FDA and Health Canada approved total artificial heart.
When did Picard Medical go public?
Picard Medical went public on December 18, 2025, ringing the Opening Bell at the New York Stock Exchange.
What is the SynCardia Total Artificial Heart?
The SynCardia Total Artificial Heart is an implantable device that fully replaces the function of a failing human heart, approved for commercial use.
How many SynCardia implants have been performed globally?
More than 2,100 SynCardia Total Artificial Heart implants have been performed in 27 countries worldwide.
Where can I find more information about Picard Medical?
For more information about Picard Medical, visit their website at www.picardmedical.com or check their SEC filings at www.sec.gov.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PMI Hedge Fund Activity
We have seen 8 institutional investors add shares of $PMI stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 244,086 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,074,731
- CITADEL ADVISORS LLC added 204,154 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,735,309
- CENTIVA CAPITAL, LP added 42,421 shares (+inf%) to their portfolio in Q3 2025, for an estimated $360,578
- XTX TOPCO LTD added 17,744 shares (+inf%) to their portfolio in Q3 2025, for an estimated $150,824
- JAIN GLOBAL LLC added 12,900 shares (+inf%) to their portfolio in Q3 2025, for an estimated $109,650
- UBS GROUP AG added 5,483 shares (+inf%) to their portfolio in Q3 2025, for an estimated $46,605
- MORGAN STANLEY added 5,060 shares (+inf%) to their portfolio in Q3 2025, for an estimated $43,010
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
TUCSON, Ariz., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada, today announced that it will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking the Company’s transition to the public markets and its continued commitment to advancing total artificial heart therapy for patients with end-stage heart failure.
“We are proud to mark Picard Medical’s transition to a newly public company,” said Patrick NJ Schnegelsberg Chief Executive Officer of Picard Medical. “Our technology has supported patients worldwide and becoming a public company strengthens our ability to advance our artificial heart platform including the fully implantable Emperor system. This marks an important next phase as we build on decades of clinical leadershippioneering the world’s first life-sustaining total artificial heart, advancing our next-generation technology and creating long-term value.”
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov .
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov .
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
[email protected]
Picard Medical, Inc./SynCardia Systems, LLC
[email protected]
General/Media
Brittany Lanza
[email protected]
